Can salanersen help Biogen defend its rare neurology franchise beyond Spinraza?
Find out how Biogen’s salanersen could reshape spinal muscular atrophy treatment after FDA breakthrough therapy status.
Pharma & Biotech
Pharma & Biotech
Why GSK’s SBP Group alliance could reshape chronic hepatitis B access in Chin
China has hepatitis B scale. GSK has bepirovirsen. SBP Group may decide whether science can become real-world access.
Pharma & Biotech
Quiver Bioscience advances Nav1.7 antisense therapy as pain drug innovation heats up
Chronic pain needs safer drugs. Quiver’s NIH-backed Nav1.7 ASO bet could test whether genetics can beat opioid-era limits.
Pharma & Biotech
Why Kardigan’s Phase 2 tonlamarsen results matter more for acute severe hypertension than chronic blood pressure care
Kardigan’s tonlamarsen showed Phase 2 promise in hypertension, but can it win in acute severe hypertension next? Read the deeper analysis.
Pharma & Biotech
Can STATHMIN-2 restoration succeed where ALS therapies have failed? QurAlis data examined
QurAlis ANQUR trial data puts STATHMIN-2 restoration on the ALS map. Find out what changes and what risks remain.
Pharma & Biotech
Could AHB-137 set a new benchmark for HBV cure rates? Insights from AusperBio’s 24-week monotherapy trial
AusperBio Therapeutics, Inc. announced that its lead investigational product, AHB-137, achieved a 30% functional cure rate as a 24-week monotherapy in HBeAg-negative chronic hepatitis B patients already on stable nucleos(t)ide analogue therapy. The data, presented at HEP-DART 2025, showed that patients with baseline HBsAg 100–1,000 IU/mL reached this endpoint at Week 72 in the company’s